Webinar: Effective IMPD Writing. The Quality Part
Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is required by competent authorities in EU.
The purpose of this webinar is to share the best practices in the preparation of IMPD in order to meet the expectations of competent authorities and to learn why effective CMC technical writing is crucial for the development of a high quality IMPD.
You will learn about:
1. Regulatory guidelines for the Investigational Medicinal Product Dossier
2. IMPD structure and content
3. Best practices for the preparation of IMPD
- Best practices in IMPD Quality writing;
- Writing style to produce accurate, concise, and clear technical text.
Starting Clinical Trials?
Make use of our expertise to smoothly prepare for clinical studies. Explore your options in a chat with one of our experts.
Who should attend? Professionals from the following fields:
- Regulatory
- R&D
- QA/QC
- Compliance
- Product Development
- Manufacturing
Duration: 40 min.
Speakers:
- Head of the Central Functions for Regulatory Affairs, Ramunė Rūkienė;
- Medical Writer, Eglė Deimantavičiūtė.
Ramunė Rūkienė, MSc
Head of Regulatory Affairs Central Operations
Other content that might interest you:
Saudi FDA’s New Pricing Guidelines and Impact on the Region
In a highly evolving regional pricing environment, Saudi Arabia (KSA) is no exception. The Saudi Food and Drug Authority (SFDA) has been periodically reviewing its pricing mechanisms and criteria so that the country becomes a regional reference for the prices of pharmaceutical products. What followed is a change in the pricing strategy by SFDA and a shift from price takers to price makers.
Marketing pharmaceutical products in CIS countries / Eurasion Union
The interest of pharmaceutical companies in expanding business across CIS region has been constantly growing. For the same reason, Biomapas has expanded presence and now covers the whole CIS region, providing core services: clinical research, regulatory affairs,...
Regulatory Strategy in the EAEU and rest of CIS Countries
Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of...
